Petrelintide vs CagriSema

Are Petrelintide and CagriSema the Same Drug?

No. Despite both targeting the amylin pathway, petrelintide and CagriSema are fundamentally different. Petrelintide is a standalone long-acting amylin analog developed by Roche and Zealand Pharma — see our full petrelintide compound profile for trial details. CagriSema is a fixed-dose combination of cagrilintide (an amylin analog) plus semaglutide 2.4 mg (a GLP-1 receptor agonist), developed by Novo Nordisk.

The distinction matters because monotherapy and combination therapy occupy very different positions in the treatment landscape. Petrelintide targets only the amylin receptor. CagriSema hits both amylin and GLP-1 receptors simultaneously — which explains its higher weight-loss numbers but also its standard GLP-1 side-effect profile.

What Is Petrelintide?

Petrelintide is a long-acting amylin analog being developed by Roche and Zealand Pharma as a once-weekly subcutaneous injection for obesity. It works by mimicking amylin, a hormone co-secreted with insulin from pancreatic beta cells that promotes satiety, slows gastric emptying, and suppresses glucagon.

The Phase 2 ZUPREME-1 trial enrolled 493 participants with overweight or obesity and reported results in March 2026. The highest dose achieved 10.7% weight loss at 42 weeks versus 1.7% for placebo. The headline finding was the tolerability profile: the drug showed a “placebo-like” safety profile with zero vomiting cases in the highest dose group and zero discontinuations due to gastrointestinal issues.

ZUPREME-2, the parallel trial in patients with type 2 diabetes, has results expected in H2 2026. Petrelintide has not been filed for FDA approval.

What Is CagriSema?

CagriSema is Novo Nordisk’s fixed-dose combination of cagrilintide (an amylin analog) and semaglutide 2.4 mg (the same GLP-1 agonist in Wegovy), administered as a once-weekly subcutaneous injection. By combining two mechanisms in a single pen, CagriSema targets both the amylin and GLP-1 pathways simultaneously. Our CagriSema amylin and GLP-1 profile covers the REDEFINE programme in full.

The REDEFINE clinical program produced strong weight-loss results: 22.7% mean body-weight reduction in the REDEFINE 1 trial (obesity without type 2 diabetes) and 15.7% in REDEFINE 2 (obesity with type 2 diabetes). Novo Nordisk filed a New Drug Application (NDA) with the FDA on December 18, 2025. If approved, CagriSema would be the first FDA-approved GLP-1/amylin combination therapy.

The FDA decision is expected in late 2026.

How Do Their Clinical Results Compare?

On headline weight-loss numbers, CagriSema leads significantly: 22.7% versus 10.7% for petrelintide. But direct comparison requires caution. These figures come from different trial designs, different patient populations, different durations (REDEFINE 1 ran longer than the 42-week ZUPREME-1), and different dose-optimization strategies. For broader context, our retatrutide vs tirzepatide vs CagriSema analysis benchmarks all three leading injectable candidates.

CagriSema’s higher efficacy is expected — it combines two active mechanisms (amylin + GLP-1) in a single drug. Petrelintide, as a monotherapy, targets only the amylin pathway. The more relevant question is not which produces more weight loss in isolation, but how petrelintide’s standalone profile positions it within the broader treatment landscape — particularly as an add-on to existing GLP-1 therapies.

Why Does Tolerability Matter So Much?

Gastrointestinal side effects are the primary reason patients discontinue GLP-1-based obesity treatments. Nausea, vomiting, and other GI issues reduce adherence and limit the real-world effectiveness of otherwise potent drugs. This is why petrelintide’s ZUPREME-1 tolerability data generated significant attention.

In the highest dose group, petrelintide recorded zero vomiting cases and zero discontinuations due to GI adverse events. Zealand Pharma described the profile as “placebo-like.” This stands in contrast to the standard GLP-1 GI profile seen with CagriSema, which includes the nausea and vomiting commonly associated with semaglutide.

For clinicians and researchers, this tolerability profile is strategically important. A drug that delivers meaningful weight loss with minimal GI burden becomes an attractive candidate for combination therapy — it could be layered on top of GLP-1 agonists without compounding the side-effect load. Explore our best research peptides 2026 guide for more on emerging compounds.

What Does This Mean for the Amylin Pipeline?

The amylin pathway is emerging as one of the most important targets in obesity research alongside GLP-1. Both petrelintide and CagriSema validate the amylin mechanism from different angles — as monotherapy and as a combination partner.

CagriSema’s NDA filing positions it as the potential first-mover in the amylin space, but petrelintide’s monotherapy approach addresses a different unmet need. A standalone amylin analog with exceptional tolerability could serve patients who cannot tolerate GLP-1 drugs, or could be added to existing GLP-1 regimens for incremental benefit without additional GI burden.

The broader pipeline also includes zenagamtide (a unimolecular GLP-1/amylin agonist) and other amylin-targeting candidates, suggesting the amylin pathway will be a major area of clinical development through 2026 and beyond. Check our CagriSema approval status page for the latest regulatory timeline.